Kimberly-Clark Completes $49 Billion Acquisition of Kenvue
Kimberly-Clark (KMB) has officially closed its acquisition of Kenvue, the consumer health company known for brands like Tylenol and Neutrogena. The deal, valued at approximately $49 billion including debt, marks a strategic expansion into the health and wellness sector to capitalize on growing consumer demand for healthy lifestyles. CEO Michael Hsu aims to leverage Kimberly-Clark's established consumer packaged goods (CPG) capabilities to accelerate growth within Kenvue’s underdeveloped product categories and improve its e-commerce strategy. The company has reaffirmed financial targets, projecting $1.9 billion in cost savings over three years and $500 million in incremental profits, though it must navigate rising input costs and legal complexities surrounding Tylenol.
Topics: acquisition completion corporate strategy financial guidance health and wellness sector
Part of the story Kimberly-Clark Completes $48.7 Billion Acquisition of Kenvue (3 articles)